Alto Neuroscience announced it raised $31.9 Million in an initial filing from an offering of $31.9 Million

Company

Location

About

Alto Neuroscience is a biopharmaceutical company redefining psychiatry through its Precision Psychiatry Platform™, which leverages individuals’ neurobiology to develop personalized and highly effective medicines that help patients get better faster. By integrating biomarkers such as EEG and wearable data, behavioral patterns, genetics, and other biological factors, Alto uses AI-driven insights to match each patient with the treatment they are most likely to respond to—bringing a new era of precision and effectiveness to mental health care.